| Project/Area Number |
15K19873
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | The University of Tokyo |
|---|
Principal Investigator |
|
|---|
| Research Collaborator |
OKU Yusuke 岩手医科大学, 薬学部, 助教
|
|---|
| Project Period (FY) |
2015-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥3,250,000 (Direct Cost: ¥2,500,000、Indirect Cost: ¥750,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2015: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Keywords | 肝細胞癌 / 化学療法 / カルシウム / ホメオスタシス |
|---|
| Outline of Final Research Achievements |
Development of effective chemotherapy is an important task for the improvement of frequent recurrence of hepatocellular carcinoma (HCC). In this study, the screening system of chemical compound using human embryonic lung fibroblast (HEL cell) was established. As the result of screening, thapsigargin (Ca2+-ATPase inhibitor) was clarified to have a particular cytotoxic effect against proliferative cells. Thapsigargin showed the cytotoxic effect against various HCC cell lines. This growth inhibitory effect was detected in the in vivo trials using hepatoma model mouse. These results suggest that Ca2+-ATPase inhibitor might be useful in the chemotherapy for HCC.
|
